Sale by Ildstad Suzanne of 16870 shares of Talaris Therapeutics

TALSDelisted Stock  USD 2.98  0.10  3.25%   
Slightly above 61% of Talaris Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Talaris Therapeutics suggests that many traders are alarmed regarding Talaris Therapeutics' prospects. Talaris Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Talaris Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Talaris Therapeutics Inc director. General open market or private sale of non-derivative or derivative security

Read at macroaxis.com
Talaris insider trading alert for sale of common stock by Ildstad Suzanne, the corporate stakeholder, on 14th of June 2023. This event was filed by Talaris Therapeutics Inc with SEC on 2023-06-14. Statement of changes in beneficial ownership - SEC Form 4

Talaris Therapeutics Fundamental Analysis

We analyze Talaris Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Talaris Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Talaris Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Talaris Therapeutics stock to make a market-neutral strategy. Peer analysis of Talaris Therapeutics could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics with similar companies.

Peers

Talaris Therapeutics Related Equities

EWTXEdgewise Therapeutics   0.53   
5.0%
NXTCNextCure   1.11   
12.0%
ACHLAchilles Therapeutics   2.02   
22.0%
TILInstil Bio   3.60   
39.0%
SPROSpero Therapeutics   3.88   
42.0%
OVIDOvid Therapeutics   4.72   
51.0%
ASMBAssembly Biosciences   5.39   
58.0%
CTMXCytomX Therapeutics   6.19   
67.0%
ACETAdicet Bio   6.25   
68.0%
CGEMCullinan Oncology   6.27   
68.0%
NUVBNuvation Bio   7.12   
77.0%
CNTBConnect Biopharma   7.55   
82.0%
VORVor Biopharma   9.18   
100.0%
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Talaris Stock

If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Stocks Directory
Find actively traded stocks across global markets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account